T2 Biosystems Reports Granting of Inducement Award
21 Julho 2023 - 5:05PM
T2 Biosystems, Inc. (NASDAQ:TTOO) a leader in the rapid detection
of sepsis-causing pathogens, announced today that it issued
inducement awards to fourteen new employees.
The awards were made on June 26, 2023, under the
T2 Biosystems’ Inducement Award Plan (the "Inducement Plan"), which
was adopted on March 1, 2018 and amended and restated on February
16, 2023 and provides for the granting of equity awards to new
employees of T2 Biosystems. The inducement awards consist of seven
option grant awards to purchase an aggregate of 33,350 shares of T2
Biosystems common stock. The exercise price of the options was
$0.0710 which was the per-share closing price of T2 Biosystems
common stock on the Nasdaq Capital Market on June 26, 2023. The
options vest over a four-year period, with 25% vesting on the first
anniversary of the employee’s date of hire and the remainder
vesting in equal monthly installments over the three years
thereafter. The stock options have a ten-year term. The award was
approved by the independent compensation committee of T2
Biosystems’ board of directors and was granted as an inducement
material to the new employee entering into employment with T2
Biosystems in accordance with Nasdaq Marketplace Rule
5635(c)(4).
About T2 Biosystems:
T2 Biosystems, a leader in the rapid detection
of sepsis-causing pathogens and antibiotic resistance genes, is
dedicated to improving patient care and reducing the cost of care
by helping clinicians effectively treat patients faster than ever
before. T2 Biosystems’ products include the T2Dx® Instrument, the
T2Bacteria® Panel, the T2Candida® Panel, the T2Resistance® Panel,
and the T2SARS-CoV-2™ Panel and are powered by the proprietary T2
Magnetic Resonance (T2MR®) technology. T2 Biosystems has an active
pipeline of future products, including the T2Biothreat™ Panel, the
Candida auris test, and T2Lyme™ Panel, as well as next-generation
products for the detection of bacterial and fungal pathogens and
associated antimicrobial resistance markers. For more information,
please visit www.t2biosystems.com.
Investor Contact:Philip Trip Taylor, Gilmartin
Groupphilip@gilmartinIR.com 415-937-5406
T2 Biosystems (NASDAQ:TTOO)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
T2 Biosystems (NASDAQ:TTOO)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024